Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
| Date | Est. | Actual | |
|---|---|---|---|
| Feb 17, 2026 | – | -$0.02 | |
| Aug 22, 2025 | – | -$0.09 | |
| May 29, 2025 | – | $47.37 | |
| Nov 14, 2024 | – | -$1.43 | |
| Aug 20, 2024 | – | -$26.98 | |
| May 28, 2024 | -$38.00 | -$32.00 | Beat |